Shenzhen Shenxin Biotechnology Co., Ltd

This study tests a new mRNA vaccine called IN001 to prevent shingles (herpes zoster) in healthy adults aged 50 to 79. About 480 participants will receive one of three doses of the study vaccine or an existing shingles vaccine, and researchers will monitor safety and immune respon…

This early-stage study tests a new mRNA vaccine called IN006 for respiratory syncytial virus (RSV) in healthy adults aged 18 to 79. The vaccine is given as one shot, with some older adults getting a booster about a year later. The main goal is to check safety and how well the vac…